Core Viewpoint - The increasing variety of ETF products has created a challenge for investors in selecting suitable options based on their investment needs, prompting several public fund institutions to report ETF-FOF products to address this issue [1][5]. Group 1: ETF-FOF Product Advantages - ETF-FOF products are recognized for their higher capital efficiency, lower fee rates, and the ability to disclose valuations on a "T+1" basis, unlike traditional FOF products which face issues like delayed valuations and double fees [3][4]. - The ETF-FOF strategy requires public fund institutions to enhance their macroeconomic research, market analysis, and asset allocation capabilities, combining both quantitative and qualitative approaches for effective asset allocation [1][6][7]. Group 2: Recent Developments and Offerings - Several public fund institutions, including China Europe Fund and Ping An Fund, have reported ETF-FOF products this year, such as the China Europe Active Multi-Asset 3-Month Holding Mixed Fund and the Ping An Yingxuan 90-Day Holding Bond Fund [2][3]. - The China Europe Active Multi-Asset 3-Month Holding Mixed Fund has been approved and started sales on May 13, with over 80% of its assets allocated to other public funds, including ETFs [3]. Group 3: Market Context and Challenges - The expansion of ETF products has provided a fertile ground for the development of ETF-FOF strategies, although existing FOF products have struggled to grow in scale, often remaining below 200 million yuan due to market adjustments in recent years [4][5]. - The current low valuation of the equity market and the rapid expansion of domestic ETF products across various categories may present a window of opportunity for ETF-FOF strategies to offer diversified asset allocation and better investment experiences [5][6].

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

Group 1 - The A-share market showed mixed performance on June 10, with the Sci-Tech Innovation Pharmaceutical Index ETF (588700) declining by 0.38% and a trading volume exceeding 30 million yuan [1] - The Sci-Tech Innovation Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals, biomedical engineering, and related sectors [1] - The Chinese government has issued guidelines to improve basic medical insurance and commercial health insurance, aiming to better meet the multi-level medication needs of the public [1] Group 2 - The innovative drug sector has experienced rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [2] - There is a trend of the innovative drug market expanding to the overall sector, with a focus on companies with large product volumes and BD expectations [2]

医药板块近期持续上行，6月首个交易日，医疗保健、制药等板块再度走强。 A股相关ETF中，科创医药指数ETF（588700）截至发稿涨超2%，盘中换手率超6%，溢折率0.12%， 溢价交易明显。成分股中，微芯生物涨超14%，神州细胞、三生国健、华熙生物等多股涨幅在8%以 上。 科创医药指数ETF（588700）紧密跟踪上证科创板生物医药指数，上证科创板生物医药指数从科创板市 场中选取50只市值较大的生物医药、生物医学工程、生物农业、生物质能、其他生物业等领域上市公司 证券作为指数样本，反映科创板市场代表性生物医药产业上市公司证券的整体表现。该ETF配备了2只 场外联接基金（A类：021060；C类：021061）。 实际上，在刚刚过去的5月份，医药板块表现强势。Wind数据显示，以申万一级行业为例，5月份，申 万医药生物指数单月涨6.42%，仅次于环保（6.83%）。 而消息面上，在5月最后一周，诸多创新药顺利获批，5月29日一日内获批创新药11款，创新药进入兑现 收获期。 国金证券指出，上周国家药监局批准11款全新创新药的上市申请，另外还有2款创新药拟纳入优先审 评，新品种密集获批有望赶上今年医保谈判放量，为 ...

Market Overview - The market experienced a rebound on May 29, with the Shanghai Composite Index rising by 0.7%, the Shenzhen Component Index increasing by 1.24%, and the ChiNext Index gaining 1.37% [1] - Over 4,400 stocks in the market rose, with more than a hundred stocks hitting the daily limit up [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.19 trillion yuan, an increase of 175.5 billion yuan compared to the previous trading day [1] Sector Performance - Leading sectors included unmanned vehicles, digital currency, software development, and innovative pharmaceuticals, while sectors such as gold, glyphosate, food, and banking saw declines [1] - The top-performing sectors experienced significant gains after a prolonged period of adjustment, indicating a recovery trend [8] Individual Stock Performance - The median increase for all stocks in the market was 1.35%, suggesting that stocks outperforming this benchmark may have more potential for sustained growth [14] - Notable sectors with recent activity included innovative pharmaceuticals, nuclear power, and unmanned vehicles, alongside emerging themes like cross-border payments and digital currency [15][16] Policy and Economic Context - The Chinese government has introduced measures to enhance cross-border financial services, which may benefit sectors related to digital currency and cross-border payments [16] - The Chairman of the China Securities Regulatory Commission emphasized the importance of market stability for economic and social stability, highlighting the government's commitment to maintaining a stable capital market [19][20][21]

Group 1 - The A-share market saw a positive trend with the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index rising by 1.95% as of the report time [1] - The Science and Technology Innovation Medicine Index ETF (588700) increased by 2.18%, with a turnover rate of 8.76% and a transaction volume exceeding 23.75 million [1] - Among the constituent stocks, Yifang Biotechnology-U surged over 12%, Borui Pharmaceutical rose over 8%, and Microchip Biotech increased over 7% [1] Group 2 - According to Industrial Securities, the innovative drug sector's prosperity is expected to be sustainable, with "innovation + internationalization" remaining the core direction of the pharmaceutical sector [2] - The report highlights that the innovative drug industry chain's fundamentals are beginning to improve, with overseas orders and performance starting to recover [2] - The demand in the domestic market is anticipated to rebound by 2025, with potential recovery in the consumption medical field, including medical services and OTC traditional Chinese medicine [2]

Core Viewpoint - The increasing variety of ETF products has created a challenge for investors in selecting suitable options based on their investment needs, prompting public fund institutions to explore ETF-FOF products as a solution [1][2]. Group 1: ETF-FOF Product Development - Multiple public fund institutions, including China Europe Fund and Ping An Fund, have reported ETF-FOF products this year, aiming to enhance investment efficiency and reduce fees [2][3]. - The ETF-FOF products are designed to invest at least 80% of their assets in other public funds, with a significant portion allocated to ETFs, thus optimizing asset allocation and enhancing returns [2][4]. Group 2: Advantages of ETF-FOF Products - ETF-FOF products offer higher capital efficiency, lower total fees, and T+1 valuation disclosure, addressing issues faced by traditional FOF products such as delayed valuation and double fees [3][4]. - The current market conditions, including low overall equity market valuations and rapid expansion of domestic ETF products, present a potential growth window for ETF-FOF products [4][5]. Group 3: Challenges and Requirements - The execution of ETF-FOF strategies faces challenges in effective strategic and tactical asset allocation, as well as selecting appropriate ETFs from a vast array of options [5][6]. - Successful implementation requires a combination of quantitative and qualitative analysis, necessitating strong macroeconomic research and market analysis capabilities within the investment teams [6].

华源证券表示，创新药：2024年创新药公司共实现营收475.3亿元，同比增长68.4%，势头强劲。国内创 新药企业已大面积走过研发周期，核心品种正处在商业化高速放量阶段。A股中有产品商业化的Biotech 创新药收入显著加速增长，同时费用相对平缓渐增，因此利润端表现更好，盈利信号清晰积极。此外， 出海授权已成为Biotech业绩第二增长曲线，高额首付款的确认提供可持续研发的资金动力支持。 国元证券表示，目前来看，中国创新药是全球最优质的资产。自 2015 年新药研发政策改革以来，中国 创新药产业链经过10年的发展，形成了临床前的优秀高效工程师、临床环节的众多患者资源和优秀三甲 医院及临床医生，创新药企业整合了这些优质资源，产生的成果得到了 MNC 的认同。美国药价政策仅 是扰动，反而会加快 MNC 推进创新药BD的步伐，我们坚定看好创新药的出海前景。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） （文章来源：21世纪经济报道） 5月14日，A股早盘缩量调整，医药板块低开震荡，相关ETF方面，科创医药指数ETF（588700）盘中小 幅回升，现跌0.11%， ...

Group 1 - The core viewpoint is that the pharmaceutical sector is focusing on innovation, with a positive trend in innovative drugs supported by policies and increasing global competitiveness [2] - The Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index has shown a 1.27% increase, indicating a recovery in the biotech sector [1] - The ETF tracking the Biomedicine Index has seen a 1.17% rise, with significant trading volume exceeding 8.12 million yuan, reflecting investor interest [1] Group 2 - The pharmaceutical industry is expected to see a recovery in demand by 2025, particularly in the consumer healthcare sector, driven by improving economic fundamentals [2] - The medical device sector is also anticipated to improve by 2025, indicating a broader recovery in the healthcare industry [2] - AI in healthcare is highlighted as a significant technological trend that could bring changes to the pharmaceutical industry [2] Group 3 - The pharmaceutical index has stabilized after a period of decline since 2021, with signs of recovery beginning in Q4 2024 [2] - The ongoing innovation in the pharmaceutical sector, along with favorable drug procurement policies, is expected to drive a new growth cycle [2] - The aging population and unmet clinical needs are contributing to long-term growth trends in the pharmaceutical industry [2]

无需50万，A股账户就能直接买科创板>> 科创医药指数ETF(588700)涨超3%，成交额1762.02万元，较昨日此时放量81.24%，近1月份额减少4750 万份。 ...